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ABSTRACT 
Objective: To develop and validate a simple and sensitive RP-HPLC method for the simultaneous determination of mometasone furoate (MOM) and 
formoterol fumarate (FOR) in pharmaceutical dosage forms. 
Methods: In RP-HPLC method, chromatographic separation was achieved using a mixture of a solvent system consisting of methanol–water (pH 
3.5) in the ratio of 85:15 % v/v at a flow rate of 1 ml/min and detection was carried out at 225 nm.  
Results: The run time for the simultaneous estimation of drugs for the proposed method was 10 min as drugs eluted at 5.217 min (MOM) and 8.650 
min (FOR). The linearity was found in the range of 33.33-299.97 μg/ml and 1-9 μg/ml for MOM and FOR, respectively. The values of limit of 
detection and limit of quantification were 3.634, 0.266 µg/ml and 11.014, 0.807 µg/ml, which indicates the sensitivity of the method for the 
estimation of MOM and FOR, respectively. The results of recovery studies for both the drugs were within the range i.e. 98.87-101.48 % which 
indicates the accuracy of the method. Relative standard deviation obtained from repeatability and reproducibility studies were less than 2% 
indicates the precision of the method. The proposed method was validated according to ICH guidelines.  
Conclusion: The proposed RP-HPLC method was found to be sensitive and precise because of the low LOD, LOQ and % RSD values (<2). The 
proposed work does not require acetonitrile and ion pairing reagent as compared to the reported methods. Therefore, method can be used 
preferably for routine analysis due to its simplicity and economic advantages. 
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Management of asthma is improved by combining inhaled 
corticosteroids with long-acting β2-agonists. Inhalation permits 
effective delivery of the drugs in high concentration to target sites 
within the lung, minimizing systemic exposure [1]. Combinational 
therapy of mometasone furoate (MOM) and formoterol fumarate 
(FOR) has been used in the treatment of COPD and asthma as it 
produces the additive effects for improving the symptoms, lung 
functions and reduces exacerbation in patient [2]. MOM (fig. 1) is a 
white crystalline powder, soluble in acetone, dichloromethane and 
slightly soluble in ethanol and a highly potent synthetic chlorinated 
glucocorticosteriod [3]. FOR (fig. 2) is a white crystalline, soluble in 
ethanol and methanol, slightly soluble in water, practically insoluble 
in acetonitrile. It appears to be more effective than shorter acting β2 
 
agoinst in the treatment of nocturnal and exercise induced asthma. 
Moreover, it acts locally in the lung as a bronchodilator [4]. 
 
Fig.1: Chemical structure o mometasone furoate 
 
 
Fig. 2: Chemical structure of FOR formoterol fumarate 
The literature survey reveals that several analytical methods have 
been published for the estimation of MOM alone and in combination 
with other drugs like fusidic acid [5], oxymetazoline [6] terbinafine 
HCl, nadifloxacin [7], eberconazole nitrate [8], miconazole, 
hydrocortisone [9], ketoconazole [10], salicylic acid [12] etc. Some of 
these methods include HPLC, GC, supercritical fluid chromatography 
and UV spectrophotometry. Various methods have also been reported 
for the estimation of FOR alone [13] and in combination with other 
drugs like budesonide [14, 16], tiotropium bromide [15] including 
HPLC, GC, and UV spectrophotometry [13-17]. 
MATERIALS AND METHODS 
A spectrophotometric 
and HPLC method for the simultaneous determination of MOM with 
FOR has also been reported in meter dose dosage form [17-19]. In one 
of the reported method, the mobile phase contained ion pairing 
reagents which will decrease the column life and was less sensitive. In 
the second method use of 60% ACN may increase the cost of analysis. 
The present study proposes a new RP-HPLC method using a mixture of 
methanol and water as a mobile phase for simultaneous estimation for 
MOM and FOR in rotacaps with the run time of 10 min. 
Instrumentation 
Younglin (S. K) gradient HPLC system combined with UV detector 
and Software–Autochro-3000 was used. Toshcon Ultrasonic Cleaner 
(Sonicator) of model SW 4 was used for sonication purpose. Digital 
Balance of Model Adventurer Pro AVG 264C (0.0001 gm to 260 gm) 
was used for weighing purpose. Digital pH meter of Model: S901was 
used for pH measurement. 
Chemicals and reagents 
Standard drugs of MOM and FOR were obtained as gift samples from 
Sun Pharmaceutical Industries Ltd., Vadodara (Gujarat) India. The 
marketed formulation (Evocort®, Cipla Ltd.) of rotacaps containing 
MOM (200 µg) and FOR (6 µg) was purchased from local market. All 
the chemicals and reagents used were of HPLC/analytical grade. 
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The separation and quantitation of MOM and FOR were made on a 
250 mm × 4.6 mm (i.d.) thermo (5 μm particle size) reversed phase 
C18 analytical column. The mobile phase was prepared by mixing 
methanol-water (pH 3.5 with 0.05 % orthophosphoric acid) in the 
ratio of 85:15 % v/v. The flow rate was set at 1 ml min-1
Preparation of standard solution 
MOM (333 mg) and FOR (10 mg) were weighed accurately and 
transferred to a 100 ml volumetric flask containing 25 ml methanol 
and sonicated. It was further diluted up to the mark with methanol 
to get 3330 μg/ml of MOM and 100 μg/ml of FOR, respectively and 
labelled as a standard stock solution. Further dilution was made to 
get required concentration. 
Analysis of sample formulation 
The powder content of twenty rotacaps (Each Rotacap contain FOR: 
6 μg; MOM: 200 μg) was accurately weighed. A portion of powder 
(403.83 mg) equivalent to 0.1 mg of FOR and 3.33 mg of MOM was 
transferred to a 10 ml volumetric flask containing 5 ml methanol. 
The solution was sonicated for 15 min and made up to mark with 
methanol and filtered through 0.45 μm membrane filter. Further 
suitable aliquots of above sample formulation were diluted using 
mobile phase to obtain the concentration of both the drugs within 
the linearity range. The solutions were injected and chromatograms 
were recorded by the proposed RP-HPLC method. Based on the peak 
area of analytes, percentage assay of the formulation was calculated. 
Method validation 
The developed method for the simultaneous determination of MOM 
and FOR was validated for specificity, linearity, precision, accuracy, 
sensitivity, robustness and system suitability according to the 
International Conference on Harmonization guidelines [20]. 
Specificity  
The selectivity of the RP HPLC method was checked by comparison 
of the chromatograms obtained from the samples and the 
corresponding placebo. The resolution factor between the MOM and 
FOR was 11.63 indicating that the method remained selective for 
both the drugs under test conditions. 
Linearity and range 
. All 
detection was carried out at ambient temperature. The injection 
volume was 20 μl. The detector was set at 225 nm wavelength. Data 
acquisition was performed by Autochro-3000 software. 
Linearity was evaluated by linear regression analysis. The linearity of the 
method was studied by analyzing different aliquots of binary mixture of 
standard solutions in the range of 33.33-299.97 μg/ml and 1-9 μg/ml for 
MOM and FOR, respectively in five replicates. Calibration graphs were 
plotted using peak areas versus concentration. The results were 
subjected to regression analysis by the least squares method to calculate 
the values of slope, intercept and correlation coefficient. 
Precision 
It was studied by carrying out repeatability, intraday and interday 
precision. Repeatability study was evaluated by analyzing the 
solution (99.99 μg/ml and 3 μg/ml of MOM and FOR) six times in 
HPLC system and % RSD was calculated. Intraday and interday 
precision was carried out by analyzing three replicate injections of 
MOM at different concentration 99.99, 166.65, 233.31 μg/ml and 
FOR 3, 5, 7 μg/ml on the same day and different day which was 
expressed in term of % RSD. 
Accuracy 
Recovery studies were carried out by the addition of standard drug 
to pre-analyzed sample solution (FOR: 3 μg/ml; MOM: 99.9 μg/ml) 
at three different levels: 50, 100 and 150 % to validate the accuracy 
parameter. The result of the accuracy study was assessed based on 
the percentage of standard FOR and MOM recovered from the 
formulation using following formula. 
% Recovery = (Amount of drug found after addition of standard 
drug–Amount of drug found before addition of standard 
drug)/(Amount of standard drug added) x 100 
 
Sensitivity  
Sensitivity was evaluated by calculating the limit of detection and 
limit of quantification of FOR and MOM using the following equation 
as per ICH guidelines. 
LOD = ×  
LOQ = 10 ×  
Where, σ = Standard deviation of the response, 
S = Slope of the calibration curve. 
Robustness  
Robustness was checked based on slight alteration in some critical 
parameters to allow routine laboratory use. It was performed by 
making slight alteration in proportion of methanol in mobile phase 
(85±2% v/v), flow rate (1±0.1 ml/min) and buffer pH (3.5±0.2 
units). The solutions were analysed, values of peak area and 
retention time were recorded. 
System suitability  
System suitability tests were performed to confirm that the 
instrument was in appropriate condition for the analysis to be 
performed. Six replicates of the standard solution was injected and 
chromatograms were recorded to confirm the suitability of the 
chromatograph. Peak area reproducibility, number of theoretical 
plates, resolution and tailing factor were recorded. 
  
 
Fig. 3: HPLC chromatogram of MOM and FOR under optimised condition 
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For developing well suited RP-HPLC method for analysis, parameters 
like detection wavelength, mobile phase composition, optimum pH 
and concentrations of the standard solution were comprehensively 
studied. The working standard solution was scanned in the range of 
190-400 nm. At 220 nm, both the drugs gave satisfactory absorbance 
with due consideration in difference of their concentration and 
absorbance intensity. Several trials were carried out with different 
ratios of methanol and water for optimization of the mobile phase. 
Water: methanol in the ratio of 15:85 % v/v gave good resolved peaks, 
but tailing was observed in FOR peak. Numerous trials of mobile phase 
in the pH range of 3-5 were also tried. A solvent system of methanol–
water (pH adjusted to 3.5 with 0.05 % ortho phosphoric acid) in the 
ratio of (85:15 % v/v) gave optimum peaks with a flow rate of 1.0 
ml/min. MOM [retention time (tR) 5.217 min] was eluted first 
followed by FOR [retention time (tR) 
The linearity range was optimized by analyzing the solution of MOM 
and FOR at different concentration range. The calibration curve was 
constructed by plotting concentration of standard solution against 
mean peak area and the regression equation was computed. The 
goodness of fit (
8.650 min] as shown in fig. 2. 
Validation of the developed method  
The developed method was validated as per ICH guidelines. The 
specificity analysis revealed the HPLC method did not suffer any 
interferences from the formulation excipients, because no other 
peaks were observed at the retention times of MOM and FOR. 
R2
The intra-day and inter-day reproducibility values, expressed as 
percent relative standard deviation were less than 2 and percent 
relative standard deviation of repeatability study was less than 1, 
which ensures the reliability of results as shown in table 1.  
) was found to be 0.9997 for both the drugs, 
indicating a linear relationship between the concentration of analyte 
and peak area, as shown in table 1. The LOD and LOQ values were, 
3.634, 11.014 µg/ml and 0.266, 0.807 µg/ml, respectively for MOM 
and FOR which indicates the sensitivity of the method.  
Accuracy was determined by comparing the amount found 
(concentration) with the amount added (concentration). The mean 
percentage recoveries were calculated for MOM and FOR. The 
results are shown in table 2 which indicates that there was no 
interference from the excipients. All parameters described under 
robustness studies were analysed, but no significant changes were 
found in retention time, peak area and symmetry of the peaks as 
mentioned in table 3. It was found that the values of system 
suitability parameters were within the acceptable limits as 
recommended in ICH guidelines (table 4).  
The amount found in percentage which were close to 100 and 
relatively low % RSD values shows that the developed method was 
successfully applied to analyze MOM and FOR in rota caps (table 5). 
 
Table 1: Results of linearity and precision studies of proposed method 
Parameters MOM FOR 
Linearity range (µg/ml) 33.33-299.97 1-9 
Correlation coefficient  0.9997 0.9991 
Regression Equation   
Slope  18.922 51.351 
Intercept -24.204 6.533 
LOD (µg/ml) 3.634 0.266 
LOQ (µg/ml) 11.014 0.807 
Precision (%RSD) *   
Repeatability of measurement (n=6) 0.751 0.827 
Intra-day (n=3) 1.207 1.211 
Inter-day (n=3) 1.605 1.700 
*n = number of determinations, % RSD (Percentage relative standard deviation).  
 
Table 2: Results of recovery studies of proposed method 
Level (%) MOM FOR 
 Recovery (%) *   RSD (%)   Recovery (%) * RSD (%)  
50 100.925±0.756 0.749 99.053±1.813 1.830 
100 101.482±0.696 0.685 98.867±1.704 1.723 
150 100.889±0.985 0.976 99.426±1.683 1.692 
*mean±SD (n=3), SD (Standard deviation), % RSD (Percentage relative standard deviation) 
 
Table 3: Results of robustness studies of the proposed method 
S. No. Modification MOM FOR 
R Peak Area t R Peak Area t 
1 Organic phase 
(85±2% v/v) 
5.134 3175.67 8.734 268.57 
2 5.148 3276.76 8.698 276.54 
3 5.248 3198.66 8.675 274.59 
% RSD* (˂2) 1.201 1.647 0.342 1.521 
1 Effect of pH 
(3.5±0.2 unit) 
5.154 3178.08 8.615 269.05 
2 5.175 3167.65 8.654 272.34 
3 5.168 3267.49 8.706 263.52 
% RSD* (˂2) 0.207 1.713 0.527 1.695 
1 Effect of flow rate 
(1±0.1 ml/min) 
5.234 3215.13 8.745 267.75 
2 5.167 3156.36 8.665 270.59 
3 5.106 3193.23 8.608 264.41 
% RSD* (˂2) 1.239 0.931 0.794 1.156 
*(n = 3), % RSD (Percentage relative standard deviation) 
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Table 4: Result of system suitability studies of the proposed method 
Parameters Values Acceptance criteria 
MOM FOR 
Peak area (% RSD)* 0.592 0.827 %RSD ≤ 2 
Retention Time (%RSD)* 0.277 0.441 %RSD ≤ 2 
No. of theoretical Plates (N) 9806.980 7447.98 N>2000 
Tailing Factor (T)* 1.182±0.112 1.378±0.144 T ≤ 2 
Resolution (RS - )* 11.865±0.396 Rs>2 
* (n = 6) number of determinations 
 
Table 5: Results of formulation analysis using the proposed RP-HPLC method 
Drugs Labelled amount (µg/rotacap) Amount found (µg/rotacap) Amount found (%)* RSD (%)** 
MOM 200 200.501±1.578 100.250±0.789 0.787 
FOR 6 5.978±0.737 99.596±1.005 1.009 
*mean±SD (n=6), SD (Standard deviation), ** % RSD (Percentage relative standard deviation) 
 
DISCUSSION 
In the growing era of international competition for maintaining the 
standard of products in high commercial and market value, 
development and validation of analytical method became obligatory. 
Analytical method development is the process of demonstrating 
whether an analytical method is acceptable for use in workplace to 
quantify the concentration of subsequent sample. The method 
development and validation should be performed as per the 
protocols and acceptance criteria set out in the ICH guideline Q2 
(R1) and used within GMP and GLP environments. In proposed HPLC 
method, chromatographic separation was achieved on reversed 
phase mode consisting of a mixture of methanol–water (pH adjusted 
to 3.5 with 0.05% ortho phosphoric acid) in the ratio of 85:15% v/v 
on thermo C18
CONCULSION 
 column at a flow rate of 1 ml/min. The run time for 
the simultaneous estimation of drugs for the proposed method was 
10 min as drugs eluted at 5.217 min (MOM) and 8.650 min (FOR). 
The tailing factor for both the peaks was found to be<1.5. The ability 
of the method to separate and accurately measure the peak of 
interests which indicate the specificity of the method. This method 
showed good linearity over the range of 33-300 µg/ml for MOM and 
1-9 µg/ml for FOR. The correlation coefficient was found to be 
greater than 0.998 which was within the limits specified (NLT 0.99). 
This gives confidence that the response and concentration are 
directly proportional. Moreover, the developed method (linearity 
range of 33-300 µg/ml for MOM and 1-9 µg/ml for FOR) was more 
sensitive than the reported method (linearity range FOR 13-193 
µg/ml and MOM 0.403-6.127 mg/ml). Precision had shown good 
results which prove that the method can be used for regular 
analysis. The standard addition and recovery studies were 
conducted to demonstrate the accuracy of the method. The recovery 
was found to be in the range of 98-102 %. So, the method can be 
used for the estimation of MOM and FOR from its dosage form, 
without any interference. In all deliberately varied conditions, the 
SD of retention time and peak area of both drugs were found to be 
within the acceptable limit. By using the above method, assay of the 
marketed formulation was carried out. The mean percentage 
recovery of the formulation was 99.60%. Present assay, the amount 
of both the drugs recovered was found to be 100.250±0.789 for 
MOM and 99.596±1.005 for FOR. Moreover, in comparison with the 
method described in the literature the proposed method was found 
to be simple, sensitive and precise. The developed HPLC method was 
cost effective for routine quality analysis as the mobile phase utilizes 
water and methanol. Hence, the developed RP-HPLC assay method, 
was found to be appropriate for the analysis of drug in their 
pharmaceutical dosage form. 
The proposed RP-HPLC method was found to be simple, sensitive, 
precise and cost-effective for simultaneous determination of MOM 
and FOR in rotacaps on account of the low LOD, LOQ and % RSD 
values (<2). The proposed work contributed advantage in case of 
HPLC method which was found to be economical because it does not 
require acetonitrile and ion pairing reagent. So, the developed 
method can be used for routine analysis in quality control 
department for analysing MOM and FOR in rotacaps.  
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